AbbVievsExelixis

ABBV and EXEL stock compared: price, dividend, valuation and results, from SEC filings.

EXEL

Exelixis, Inc.

$67.10

Value $16.4B

-2.75%
EXEL's page

AbbVie (ABBV) has a market value of $521B and Exelixis (EXEL) $16.4B. Over the last year, with dividends, ABBV moved +30.6% and EXEL +61.1%. The P/E is 50.6 for ABBV and 18.5 for EXEL. Dividend yield: ABBV 2.35%, EXEL none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    ABBV$521B

    EXEL$16.4B

    ABBV is 32 times EXEL

  • Revenue, 12 months

    ABBV$66.0B

    EXEL$2.5B

    ABBV is 26 times EXEL

  • Net income, 12 months

    ABBV$10.3B

    EXEL$885M

    ABBV is 12 times EXEL

  • Operating margin

    ABBV32.2%

    EXEL40.2%

    8.0 points apart

  • ROIC

    ABBV25.7%

    EXEL39.9%

    14.2 points apart

  • P/E

    ABBV50.6

    EXEL18.5

    ABBV is 2.7 times EXEL

  • Dividend yield

    ABBV2.4%

    EXEL0.0%

    2.4 points apart

  • 5-year return

    ABBV+201.4%

    EXEL+271.3%

    69.9 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

ABBV+201.4%

EXEL+271.3%

10020030040020222023202420252026
Returns by period
PeriodABBVWith dividendsEXELWith dividends
1 year since November 14, 2025+30.6%Price +26.8%+61.1%Price +61.1%
3 years since November 16, 2023+135.5%+33.0% a yearPrice +113.0%+219.8%+47.3% a yearPrice +219.8%
5 years since November 15, 2021+201.4%+24.7% a yearPrice +152.1%+271.3%+30.0% a yearPrice +271.3%
10 years since November 16, 2016+619.6%+21.8% a yearPrice +378.6%+303.5%+15.0% a yearPrice +303.5%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

ABBVAbbVieEXELExelixis

Valuation

ABBVEXEL
Valuation
Price$294.55$67.10
Market value$521B$16.4B
Enterprise value (EV)$591B$15.5B
P/E50.618.5
P/E, 5-year median57.025.4
P/B–8.9
EV/EBIT27.815.4
Free cash flow yield3.6%7.1%

Results and growth

ABBVEXEL
Results and growth
Revenue, 12 months$66.0B$2.5B
Net income, 12 months$10.3B$885M
Free cash flow, 12 months$18.9B$1.2B
Earnings per share, 12 months$5.81$3.34
Revenue growth, year on year8.6%7.0%
Revenue growth a year, past+5.9%over 5 years+18.6%over 5 years
EPS growth a year, past-2.8%over 5 years+51.3%over 5 years

Margins and returns on capital

ABBVEXEL
Margins and returns on capital
Gross margin73.7%96.3%
Operating margin32.2%40.2%
Net margin15.7%35.4%
ROIC25.7%39.9%
ROE–44.5%

Balance sheet

ABBVEXEL
Balance sheet
Cash$10.8B$892M
Total debt$80.9B$162M
Net debt / EBITDA3.2-0.9
Interest cover7.1×–

Dividends and buybacks

ABBVEXEL
Dividends and buybacks
Dividend yield2.4%–
Dividend per share, 12 months$6.92–
Dividend growth a year, past+6.6%over 5 years–
Buyback yield0.2%5.8%
Shareholder yield2.5%5.8%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: ABBV or EXEL

Didn't find what you were looking for?

Ask us
Which is bigger, AbbVie or Exelixis?

By market value, AbbVie ($521B) is about 31.8 times Exelixis ($16.4B), at today's prices.

How did ABBV and EXEL stock do over the last 10 years?

Since November 16, 2016, ABBV's price moved +378.6% and EXEL's +303.5%. With dividends: ABBV +619.6% (+21.8% a year), EXEL +303.5% (+15.0% a year). Past returns do not predict future ones.

Which pays the higher dividend, ABBV or EXEL?

The dividend yield at today's price is 2.35% for AbbVie and none for Exelixis. Over the last twelve months they paid $6.92 and – per share.

What is the P/E of ABBV and EXEL?

At today's price, the P/E is 50.6 for ABBV and 18.5 for EXEL. The median of the last five years was 57.0 and 25.4, which shows where each stands against its own past.

Which has the higher profit margins, AbbVie or Exelixis?

Over the last twelve months, the net margin was 15.7% for AbbVie and 35.4% for Exelixis, and the operating margin 32.2% and 40.2%. Revenue was $66.0B and $2.5B.

Which is the better investment, AbbVie or Exelixis?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.